Guotai Haitong Sticks to Its Buy Rating for Duality Biotherapeutics, Inc. (9606)
I'm PortAI, I can summarize articles.
Guotai Haitong analyst maintained a Buy rating on Duality Biotherapeutics, Inc. yesterday and set a price target of HK$455.56.Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Duality Biotherapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of HK$488.96.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments